Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 151-153

  Langer, Seppo W ^a   Jensen, Peter Buhl ^a   Sehested, Maxwell ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Anthracycline; Dexrazoxane; Doxorubicin; Extravasation; Savene

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIDOTE; DIMETHYL SULFOXIDE; HYDROCORTISONE; RAZOXANE;

CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG USE; EXTRAVASATION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HEART DISEASES; HUMANS; MICE; RAZOXANE;

EID: 34548317053     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0021-5     Document Type: Conference Paper

References (10)

1. Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Dermant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389-393.
2. Langer, S. W., Sehested, M., & Jensen, P. B. (2000). Treatment of anthracycline extravasation with dexrazoxane. Clinical Cancer Research, 6, 3680-3686.
3. Langer, S. W., Sehested, M., & Jensen, P. B. (2001). Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annual Oncology, 12, 405-410.
4. Langer, S.W., Thougaard, A. V., & Sehested. M et al. (2006). Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 57, 125-128.
5. Langer, S. W., Sehested, M., & Jensen, P. B. et al. (2000). Dexrazoxane in anthracycline extravasation. Journal of Clinical Oncology, 18, 3064.
6. Bos, A. M., van der Graaf, W. T., & Willemse, P. H. (2001). A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncology, 40, 541-542.
7. Jensen, J. N., Lock-Andersen, J., & Langer, S. W. et al. (2003). Dexrazoxane - a promising antidote in the treatment of accidental extravasation of anthracyclines. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 37, 174-175.
8. El Saghir, N., Otrock, Z., & Mufarrij, A. et al. (2004). Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncology, 5, 320-321.
9. Mouridsen, H. T., Langer, S.W., & Buter, J. et al. (2006). Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annual Oncology, Dec 21.
10. Mouridsen, H. T. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane). Results from two prospective clinical multicenter studies. Annals of Oncology. (In press).